nach oben

Current Oncology Reports

Erschienen in:

01.03.2015 | Pediatric Oncology (S Epelman, Section Editor)

Pediatric Brainstem Gliomas: New Understanding Leads to Potential New Treatments for Two Very Different Tumors

verfasst von: Adam L. Green, Mark W. Kieran

Erschienen in: Current Oncology Reports | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Pediatric brainstem gliomas include low-grade focal brainstem gliomas (FBSG) and high-grade diffuse intrinsic pontine gliomas (DIPG). These tumors share a crucial and eloquent area of the brain as their location, which carries common challenges for treatment. Otherwise, though, these two diseases are very different in terms of presentation, biology, treatment, and prognosis. FBSG usually present with greater than 3 months of symptoms, while DIPG are usually diagnosed within 3 months of symptom onset. Surgery remains the preferred initial treatment for FBSG, with chemotherapy used for persistent, recurrent, or inoperable disease; conversely, radiation is the only known effective treatment for DIPG. Recent developments in biological understanding of both tumors have led to new treatment possibilities. In FBSG, two genetic changes related to BRAF characterize the majority of tumors, and key differences in their biological effects are informing strategies for targeted chemotherapy use. In DIPG, widespread histone H3 and ACVR1 mutations have led to new hope for effective targeted treatments. FBSG has an excellent prognosis, while the long-term survival rate of DIPG tragically remains near zero. In this review, we cover the epidemiology, biology, presentation, imaging characteristics, multimodality treatment, and prognosis of FBSG and DIPG, with a focus on recent biological discoveries.

Fisher PG, Breiter SN, Carson BS, Wharam MD, Williams JA, Weingart JD, et al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer. 2000;89(7):1569–76.PubMed

Jeuken JW, Wesseling P. MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. J Pathol. 2010;222(4):324–8. doi:10.1002/path.2780.PubMed

Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A, et al. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer. 2009;101(4):722–33. doi:10.1038/sj.bjc.6605179.PubMedCentralPubMed

Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2008;67(9):878–87. doi:10.1097/NEN.0b013e3181845622.PubMed

Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008;118(5):1739–49. doi:10.1172/JCI33656.PubMedCentralPubMed

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397–405. doi:10.1007/s00401-011-0802-6.PubMed

Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PloS One. 2011;6(3):e17948. doi:10.1371/journal.pone.0017948.PubMedCentralPubMed

MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, et al. Profiling critical cancer gene mutations in clinical tumor samples. PloS One. 2009;4(11):e7887. doi:10.1371/journal.pone.0007887.PubMedCentralPubMed

Epstein FJ, Farmer JP. Brain-stem glioma growth patterns. J Neurosurg. 1993;78(3):408–12. doi:10.3171/jns.1993.78.3.0408.PubMed

10.

Robertson PL, Allen JC, Abbott IR, Miller DC, Fidel J, Epstein FJ. Cervicomedullary tumors in children: a distinct subset of brainstem gliomas. Neurology. 1994;44(10):1798–803.PubMed

11.

Patankar AP. Hemi-chorea: an unusual presentation of brainstem glioma. Br J Neurosurg. 2013;27(2):256–8. doi:10.3109/02688697.2012.741738.PubMed

12.

Darken RS, Bogitch R, Leonard J, Perry A, McKinstry RC, Gutmann DH, et al. Brainstem glioma presenting as pruritus in children with neurofibromatosis-1. J Pediatr Hematol Oncol. 2009;31(12):972–6. doi:10.1097/MPH.0b013e3181b8701f.PubMed

13.

Sun B, Wang CC, Wang J. MRI characteristics of midbrain tumours. Neuroradiology. 1999;41(3):158–62.PubMed

14.

Barkovich AJ, Krischer J, Kun LE, Packer R, Zimmerman RA, Freeman CR, et al. Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg. 1990;16(2):73–83.PubMed

15.

Yin L, Zhang L. Correlation between MRI findings and histological diagnosis of brainstem glioma. Can J Neurol Sci Le Journal Canadien des Sciences Neurologiques. 2013;40(3):348–54.

16.

Lui YW, Law M, Chacko-Mathew J, Babb JS, Tuvia K, Allen JC, et al. Brainstem corticospinal tract diffusion tensor imaging in patients with primary posterior fossa neoplasms stratified by tumor type: a study of association with motor weakness and outcome. Neurosurgery. 2007;61(6):1199–207. doi:10.1227/01.neu.0000306098.38141.81. discussion 207-8.PubMed

17.

Warren KE, Frank JA, Black JL, Hill RS, Duyn JH, Aikin AA, et al. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol: Off J Am Soc Clin Oncol. 2000;18(5):1020–6.

18.

Astrakas LG, Zurakowski D, Tzika AA, Zarifi MK, Anthony DC, De Girolami U, et al. Noninvasive magnetic resonance spectroscopic imaging biomarkers to predict the clinical grade of pediatric brain tumors. Clin Cancer Res : Off J Am Assoc Cancer Res. 2004;10(24):8220–8. doi:10.1158/1078-0432.CCR-04-0603.

19.

Lazareff JA, Bockhorst KH, Curran J, Olmstead C, Alger JR. Pediatric low-grade gliomas: prognosis with proton magnetic resonance spectroscopic imaging. Neurosurgery. 1998;43(4):809–17. discussion 17-8.PubMed

20.

Van Poppel K, Broniscer A, Patay Z, Morris EB. Alexander disease: an important mimicker of focal brainstem glioma. Pediatr Blood Cancer. 2009;53(7):1355–6. doi:10.1002/pbc.22232.PubMedCentralPubMed

21.

Park KY, Ahn JY, Cho JH, Choi YC, Lee KS. Neuromyelitis optica with brainstem lesion mistaken for brainstem glioma. Case Report J Neurosurg. 2007;107(3 Suppl):251–4. doi:10.3171/PED-07/09/251.

22.

Tronnier VM, Wirtz CR, Knauth M, Lenz G, Pastyr O, Bonsanto MM, et al. Intraoperative diagnostic and interventional magnetic resonance imaging in neurosurgery. Neurosurgery. 1997;40(5):891–900. discussion -2.PubMed

23.

Teo C, Siu TL. Radical resection of focal brainstem gliomas: is it worth doing? Child's Nervous System : ChNS : Off J Int Soc Pediatr Neurosurg. 2008;24(11):1307–14. doi:10.1007/s00381-008-0647-z.

24.

Recinos PF, Sciubba DM, Jallo GI. Brainstem tumors: where are we today? Pediatr Neurosurg. 2007;43(3):192–201. doi:10.1159/000098831.PubMed

25.

Wisoff JH, Sanford RA, Heier LA, Sposto R, Burger PC, Yates AJ, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurgery. 2011;68(6):1548–54. doi:10.1227/NEU.0b013e318214a66e. discussion 54-5.PubMed

26.

Di Maio S, Gul SM, Cochrane DD, Hendson G, Sargent MA, Steinbok P. Clinical, radiologic and pathologic features and outcome following surgery for cervicomedullary gliomas in children. Child's Nervous System : ChNS : Off J Int Soc Pediatric Neurosurg. 2009;25(11):1401–10. doi:10.1007/s00381-009-0956-x.

27.•

Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales La Madrid A, Marcus KJ, et al. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatric blood & cancer. 2014;61(7):1173–9. doi:10.1002/pbc.24958. This report highlighted the importance of the "first do no harm" strategy in pediatric low-grade glioma, given the excellent overall long-term outcomes but clear long-term risk of treatment with radiation.

28.

Pirotte BJ, Lubansu A, Massager N, Wikler D, Goldman S, Levivier M. Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg. 2007;107(5 Suppl):392–9. doi:10.3171/PED-07/11/392.PubMed

29.

Perez-Gomez JL, Rodriguez-Alvarez CA, Marhx-Bracho A, Rueda-Franco F. Stereotactic biopsy for brainstem tumors in pediatric patients. Child's Nervous System : ChNS : Off J Int Soc Pediatr Neurosurg. 2010;26(1):29–34. doi:10.1007/s00381-009-1000-x.

30.

Li KW, Roonprapunt C, Lawson HC, Abbott IR, Wisoff J, Epstein F, et al. Endoscopic third ventriculostomy for hydrocephalus associated with tectal gliomas. Neurosurg Focus. 2005;18(6A):E2.PubMed

31.

Bowers DC, Georgiades C, Aronson LJ, Carson BS, Weingart JD, Wharam MD, et al. Tectal gliomas: natural history of an indolent lesion in pediatric patients. Pediatric neurosurgery. 2000;32(1):24–9.PubMed

32.

Ternier J, Wray A, Puget S, Bodaert N, Zerah M, Sainte-Rose C. Tectal plate lesions in children. J Neurosurg. 2006;104(6 Suppl):369–76. doi:10.3171/ped.2006.104.6.369.PubMed

33.•

Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(21):2641–7. doi:10.1200/JCO.2011.36.6054. This randomized controlled trial compared the two most common chemotherapy regimens used for pediatric low-grade glioma. It showed an improved 5-year event-free survival for TPCV versus vincristine-carboplatin, although this advantage is tempered by the long-term risks associated with alkylators.

34.

Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol: Off J Am Soc Clin Oncol. 1993;11(5):850–6.

35.

Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747–54. doi:10.3171/jns.1997.86.5.0747.PubMed

36.

Ronghe M, Hargrave D, Bartels U, Tabori U, Vaidya S, Chandler C, et al. Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem. Pediatr Blood Cancer. 2010;55(3):471–7. doi:10.1002/pbc.22557.PubMed

37.

Prados MD, Edwards MS, Rabbitt J, Lamborn K, Davis RL, Levin VA. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neuro-Oncol. 1997;32(3):235–41.

38.

Gururangan S, Cavazos CM, Ashley D, Herndon 2nd JE, Bruggers CS, Moghrabi A, et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol : Off J Am Soc Clin Oncol. 2002;20(13):2951–8.

39.

Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM. Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer. 2007;49(6):808–11. doi:10.1002/pbc.21270.PubMed

40.

Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children’s Oncology Group. Cancer. 2007;110(7):1542–50. doi:10.1002/cncr.22961.PubMed

41.

Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(12):1358–63. doi:10.1200/JCO.2011.34.5843.

42.

Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas—a Pediatric Brain Tumor Consortium study. Neuro-Oncology. 2014;16(2):310–7. doi:10.1093/neuonc/not154.PubMedCentralPubMed

43.

Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2013;60(5):776–82. doi:10.1002/pbc.24297.PubMed

44.

Kieran M, Yao X, Macy M, Leary S, Cohen K, MacDonald T, et al. Final results of a prospective multi-institutional phase II study of everolimus (RAD001), an MTOR inhibitor, in pediatric patients with recurrent or progressive low-grade glioma: a POETIC Consortium trial. Neuro-oncology. 2014;16(3):iii27.

45.

Robison NJ, Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014;61(4):636–42. doi:10.1002/pbc.24794.PubMedCentralPubMed

46.

Kieran MW. Targeting BRAF in pediatric brain tumors. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2014:e436-40. doi: 10.14694/EdBook_AM.2014.34.e436.

47.

Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427–30. doi:10.1038/nature08902.PubMedCentralPubMed

48.••

Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci USA. 2013;110(15):5957–62. doi:10.1073/pnas.1219232110. This study determined the biological basis for the differential response to BRAF inhibitors between tumors harboring the V600E mutation versus the KIAA1549-BRAF fusion. This finding emphasized the diagnostic distinction and dual treatment strategies necessary for FBSG with mutant versus duplicated BRAF.PubMedCentralPubMed

49.

Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, et al. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-Oncology. 2014;16(10):1408–16. doi:10.1093/neuonc/nou059.PubMed

50.

Pierre-Kahn A, Hirsch JF, Vinchon M, Payan C, Sainte-Rose C, Renier D, et al. Surgical management of brain-stem tumors in children: results and statistical analysis of 75 cases. J Neurosurg. 1993;79(6):845–52. doi:10.3171/jns.1993.79.6.0845.PubMed

51.

Robertson PL, Muraszko KM, Brunberg JA, Axtell RA, Dauser RC, Turrisi AT. Pediatric midbrain tumors: a benign subgroup of brainstem gliomas. Pediatr Neurosurg. 1995;22(2):65–73.PubMed

52.

Yoshimura J, Onda K, Tanaka R, Takahashi H. Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. Neurol Med Chir. 2003;43(8):375–82. discussion 82.

53.

Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012;124(3):439–47. doi:10.1007/s00401-012-0998-0.PubMedCentralPubMed

54.••

Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature genetics. 2012;44(3):251–3. doi:10.1038/ng.1102. This report, and the one by Schwartzentruber et al, were published concurrently and documented, for the first time, the novel histone H3 mutations found in a majority of patient DIPG samples. They documented the first known regulatory histone driver mutations in human disease and began a cascade of major genetic findings in DIPG using next-generation methods on newly-available patient samples.PubMedCentralPubMed

55.

Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013;340(6134):857–61. doi:10.1126/science.1232245.PubMedCentralPubMed

56.

Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet. 2014;46(5):451–6. doi:10.1038/ng.2936.PubMedCentralPubMed

57.

Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014;46(5):462–6. doi:10.1038/ng.2950.PubMedCentralPubMed

58.

Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014;46(5):457–61. doi:10.1038/ng.2925.PubMedCentralPubMed

59.

Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46(5):444–50. doi:10.1038/ng.2938.PubMedCentralPubMed

60.

Grill J, Puget S, Andreiuolo F, Philippe C, MacConaill L, Kieran MW. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2012;58(4):489–91. doi:10.1002/pbc.24060.PubMed

61.

Puget S, Philippe C, Bax DA, Job B, Varlet P, Junier MP, et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PloS One. 2012;7(2):e30313. doi:10.1371/journal.pone.0030313.PubMedCentralPubMed

62.

Buczkowicz P, Zarghooni M, Bartels U, Morrison A, Misuraca KL, Chan T, et al. Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma. Brain Pathol. 2013;23(3):244–53. doi:10.1111/j.1750-3639.2012.00633.x.PubMed

63.

Saratsis AM, Yadavilli S, Magge S, Rood BR, Perez J, Hill DA, et al. Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid. Neuro-Oncology. 2012;14(5):547–60. doi:10.1093/neuonc/nos067.PubMed

64.

Joshi BH, Puri RA, Leland P, Varricchio F, Gupta G, Kocak M, et al. Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. Neuro-Oncology. 2008;10(3):265–74. doi:10.1215/15228517-2007-066.PubMedCentralPubMed

65.

Zhou Z, Luther N, Ibrahim GM, Hawkins C, Vibhakar R, Handler MH, et al. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neuro-Oncol. 2013;111(3):257–64. doi:10.1007/s11060-012-1021-2.

66.

Wolff JE, Rytting M, Vats T, Ater J, Mahajan A, Woo S, et al. Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer Center. Anticancer Res. 2011;31(6):2265–9.PubMed

67.

Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol : Off J Am Soc Clin Oncol. 2011;29(30):3999–4006. doi:10.1200/JCO.2011.35.5677.

68.

Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–31. doi:10.1038/nature10833.PubMed

69.

Barrow J, Adamowicz-Brice M, Cartmill M, MacArthur D, Lowe J, Robson K, et al. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro-Oncology. 2011;13(2):212–22. doi:10.1093/neuonc/noq158.PubMedCentralPubMed

70.

Chen HJ, Panigrahy A, Dhall G, Finlay JL, Nelson Jr MD, Bluml S. Apparent diffusion and fractional anisotropy of diffuse intrinsic brain stem gliomas. AJNR Am J Neuroradiol. 2010;31(10):1879–85. doi:10.3174/ajnr.A2179.PubMed

71.

Lobel U, Sedlacik J, Sabin ND, Kocak M, Broniscer A, Hillenbrand CM, et al. Three-dimensional susceptibility-weighted imaging and two-dimensional T2*-weighted gradient-echo imaging of intratumoral hemorrhages in pediatric diffuse intrinsic pontine glioma. Neuroradiology. 2010;52(12):1167–77. doi:10.1007/s00234-010-0771-9.PubMedCentralPubMed

72.

Sethi R, Allen J, Donahue B, Karajannis M, Gardner S, Wisoff J, et al. Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neuro-Oncol. 2011;102(1):121–7. doi:10.1007/s11060-010-0301-y.

73.

Poussaint TY, Kocak M, Vajapeyam S, Packer RI, Robertson RL, Geyer R, et al. MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro-Oncology. 2011;13(4):417–27. doi:10.1093/neuonc/noq200.PubMedCentralPubMed

74.

Hargrave D, Chuang N, Bouffet E. Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neuro-Oncol. 2008;86(3):313–9. doi:10.1007/s11060-007-9473-5.

75.

Hankinson TC, Campagna EJ, Foreman NK, Handler MH. Interpretation of magnetic resonance images in diffuse intrinsic pontine glioma: a survey of pediatric neurosurgeons. J Neurosurg Pediatr. 2011;8(1):97–102. doi:10.3171/2011.4.PEDS1180.PubMed

76.

Ogiwara H, Morota N. The efficacy of a biopsy of intrinsic brainstem lesions for decision making of the treatments. Child's Nervous System : ChNS : Off J Int Soc Pediatr Neurosurg. 2013;29(5):833–7. doi:10.1007/s00381-013-2042-7.

77.

Rajshekhar V, Moorthy RK. Status of stereotactic biopsy in children with brain stem masses: insights from a series of 106 patients. Stereotact Funct Neurosurg. 2010;88(6):360–6. doi:10.1159/000319044.PubMed

78.

Wang ZJ, Rao L, Bhambhani K, Miller K, Poulik J, Altinok D, et al. Diffuse intrinsic pontine glioma biopsy: a single institution experience. Pediatr Blood Cancer. 2014. doi:10.1002/pbc.25224.PubMedCentral

79.

Walker DA, Liu J, Kieran M, Jabado N, Picton S, Packer R, et al. A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro-Oncology. 2013;15(4):462–8. doi:10.1093/neuonc/nos330.PubMedCentralPubMed

80.

Kieran MW. Time to rethink the unthinkable: upfront biopsy of children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Pediatr Blood Cancer. 2014. doi:10.1002/pbc.25266.PubMedCentral

81.

Yamasaki F, Kurisu K, Kajiwara Y, Watanabe Y, Takayasu T, Akiyama Y, et al. Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma. Neuro-Oncology. 2011;13(7):791–801. doi:10.1093/neuonc/nor038.PubMedCentralPubMed

82.

Steffen-Smith EA, Shih JH, Hipp SJ, Bent R, Warren KE. Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma. J Neuro-Oncol. 2011;105(2):365–73. doi:10.1007/s11060-011-0601-x.

83.

Lobel U, Sedlacik J, Reddick WE, Kocak M, Ji Q, Broniscer A, et al. Quantitative diffusion-weighted and dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging analysis of T2 hypointense lesion components in pediatric diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol. 2011;32(2):315–22. doi:10.3174/ajnr.A2277.PubMedCentralPubMed

84.

Sedlacik J, Winchell A, Kocak M, Loeffler RB, Broniscer A, Hillenbrand CM. MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol. 2013;34(7):1450–5. doi:10.3174/ajnr.A3421.PubMedCentralPubMed

85.

Prabhu SP, Ng S, Vajapeyam S, Kieran MW, Pollack IF, Geyer R, et al. DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium. Child's Nervous System : ChNS : Off J Int Soc Pediatr Neurosurg. 2011;27(1):11–8. doi:10.1007/s00381-010-1323-7.

86.

Steffen-Smith EA, Venzon DJ, Bent RS, Hipp SJ, Warren KE. Single- and multivoxel proton spectroscopy in pediatric patients with diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2012;84(3):774–9. doi:10.1016/j.ijrobp.2012.01.032.PubMedCentralPubMed

87.

Ko C, Kaushal A, Hammoud DA, Steffen-Smith EA, Bent R, Citrin D, et al. Role of early postradiation magnetic resonance imaging scans in children with diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2012;83(4):1252–6. doi:10.1016/j.ijrobp.2011.09.046.PubMed

88.

Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children’s Cancer Group. Neurosurgery. 1993;33(6):1026–9. discussion 9-30.PubMed

89.

Pai Panandiker AS, Wong JK, Nedelka MA, Wu S, Gajjar A, Broniscer A. Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2014;61(7):1180–3. doi:10.1002/pbc.24971.PubMed

90.•

Zaghloul MS, Eldebawy E, Ahmed S, Mousa AG, Amin A, Refaat A, et al. Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014;111(1):35–40. doi:10.1016/j.radonc.2014.01.013. Several studies have examined hypofractionated radiotherapy in DIPG, but as a randomized controlled trial, this study represents the highest quality data we have on the topic. It showed measurably, but not significantly, shorter survival for patients treated with a hypofractionated regimen and raised this strategy as a viable option for patients and families most interested in quality of life.

91.

Janssens GO, Jansen MH, Lauwers SJ, Nowak PJ, Oldenburger FR, Bouffet E, et al. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys. 2013;85(2):315–20. doi:10.1016/j.ijrobp.2012.04.006.PubMed

92.

Janssens GO, Gidding CE, Van Lindert EJ, Oldenburger FR, Erasmus CE, Schouten-Meeteren AY, et al. The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children: a pilot study. Int J Radiat Oncol Biol Phys. 2009;73(3):722–6. doi:10.1016/j.ijrobp.2008.05.030.PubMed

93.

Negretti L, Bouchireb K, Levy-Piedbois C, Habrand JL, Dhermain F, Kalifa C, et al. Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution’s experience. J Neuro-Oncol. 2011;104(3):773–7. doi:10.1007/s11060-011-0542-4.

94.•

Fontanilla HP, Pinnix CC, Ketonen LM, Woo SY, Vats TS, Rytting ME, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. American journal of clinical oncology. 2012;35(1):51–7. doi:10.1097/COC.0b013e318201a2b7. This study demonstrated the feasibility of reirradiation for patients with recurrent DIPG and showed that this strategy can potentially prolong survival, especially for patients who had a good response to their initial course of RT.PubMed

95.

Wolff JE, Rytting ME, Vats TS, Zage PE, Ater JL, Woo S, et al. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neuro-Oncol. 2012;106(2):391–7. doi:10.1007/s11060-011-0677-3.

96.

Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro-Oncology. 2011;13(4):410–6. doi:10.1093/neuonc/noq205.PubMedCentralPubMed

97.

Bailey S, Howman A, Wheatley K, Wherton D, Boota N, Pizer B, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy—results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer. 2013;49(18):3856–62. doi:10.1016/j.ejca.2013.08.006.PubMedCentralPubMed

98.

Chassot A, Canale S, Varlet P, Puget S, Roujeau T, Negretti L, et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neuro-Oncol. 2012;106(2):399–407. doi:10.1007/s11060-011-0681-7.

99.

Sharp JR, Bouffet E, Stempak D, Gammon J, Stephens D, Johnston DL, et al. A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Eur J Cancer. 2010;46(18):3271–9. doi:10.1016/j.ejca.2010.06.115.PubMed

100.

Chiang KL, Chang KP, Lee YY, Huang PI, Hsu TR, Chen YW, et al. Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution. Child's Nervous System : ChNS : Off J Int Soc PediatrNeurosurg. 2010;26(8):1035–41. doi:10.1007/s00381-010-1106-1.

101.

Jalali R, Raut N, Arora B, Gupta T, Dutta D, Munshi A, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2010;77(1):113–8. doi:10.1016/j.ijrobp.2009.04.031.PubMed

102.

Broniscer A, Iacono L, Chintagumpala M, Fouladi M, Wallace D, Bowers DC, et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer. 2005;103(1):133–9. doi:10.1002/cncr.20741.PubMed

103.

Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res : Off J Am Assoc Cancer Res. 2013;19(11):3050–8. doi:10.1158/1078-0432.CCR-13-0306.

104.

Warren K, Bent R, Wolters PL, Prager A, Hanson R, Packer R, et al. A phase 2 study of pegylated interferon alpha-2b (PEG-Intron(R)) in children with diffuse intrinsic pontine glioma. Cancer. 2012;118(14):3607–13. doi:10.1002/cncr.26659.PubMedCentralPubMed

105.

Pollack IF, Stewart CF, Kocak M, Poussaint TY, Broniscer A, Banerjee A, et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro-Oncology. 2011;13(3):290–7. doi:10.1093/neuonc/noq199.PubMedCentralPubMed

106.

Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro-Oncology. 2011;13(1):109–18. doi:10.1093/neuonc/noq141.PubMedCentralPubMed

107.

Michalski A, Bouffet E, Taylor RE, Hargrave D, Walker D, Picton S, et al. The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. J Neuro-Oncol. 2010;100(1):81–8. doi:10.1007/s11060-010-0141-9.

108.

Ohno M, Natsume A, Fujii M, Ito M, Wakabayashi T. Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma. Pediatr Blood Cancer. 2009;53(1):37–41. doi:10.1002/pbc.21987.PubMed

109.

Haas-Kogan DA, Banerjee A, Kocak M, Prados MD, Geyer JR, Fouladi M, et al. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro-Oncology. 2008;10(3):341–7. doi:10.1215/15228517-2008-004.PubMedCentralPubMed

110.

Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, et al. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neuro-Oncol. 2012;106(3):643–9. doi:10.1007/s11060-011-0709-z.

111.

Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(18):3069–75. doi:10.1200/JCO.2009.26.8789.

112.

Fouladi M, Nicholson HS, Zhou T, Laningham F, Helton KJ, Holmes E, et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children’s Oncology Group study. Cancer. 2007;110(11):2535–41. doi:10.1002/cncr.23078.PubMed

113.

Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey 2nd WH, et al. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro-Oncology. 2008;10(2):112–20. doi:10.1215/15228517-2007-052.PubMedCentralPubMed

114.

Barua NU, Lowis SP, Woolley M, O'Sullivan S, Harrison R, Gill SS. Robot-guided convection-enhanced delivery of carboplatin for advanced brainstem glioma. Acta Neurochir. 2013;155(8):1459–65. doi:10.1007/s00701-013-1700-6.PubMed

115.

Massimino M, Spreafico F, Biassoni V, Simonetti F, Riva D, Trecate G, et al. Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neuro-Oncol. 2008;87(3):355–61. doi:10.1007/s11060-008-9525-5.

116.

Broniscer A, Laningham FH, Kocak M, Krasin MJ, Fouladi M, Merchant TE, et al. Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma. Cancer. 2006;106(6):1364–71. doi:10.1002/cncr.21749.PubMed

117.

Jackson S, Patay Z, Howarth R, Pai Panandiker AS, Onar-Thomas A, Gajjar A, et al. Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma. J Neuro-Oncol. 2013;114(3):339–44. doi:10.1007/s11060-013-1189-0.

118.

Caretti V, Jansen MH, van Vuurden DG, Lagerweij T, Bugiani M, Horsman I, et al. Implementation of a multi-institutional diffuse intrinsic pontine glioma autopsy protocol and characterization of a primary cell culture. Neuropathol Appl Neurobiol. 2013;39(4):426–36. doi:10.1111/j.1365-2990.2012.01294.x.PubMed

119.

Broniscer A, Baker JN, Baker SJ, Chi SN, Geyer JR, Morris EB, et al. Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer. 2010;116(19):4632–7. doi:10.1002/cncr.25405.PubMedCentralPubMed

120.

Angelini P, Hawkins C, Laperriere N, Bouffet E, Bartels U. Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances. J Neuro-Oncol. 2011;101(1):75–81. doi:10.1007/s11060-010-0224-7.

121.

Siu IM, Tyler BM, Chen JX, Eberhart CG, Thomale UW, Olivi A, et al. Establishment of a human glioblastoma stemlike brainstem rodent tumor model. J Neurosurg Pediatr. 2010;6(1):92–7. doi:10.3171/2010.3.PEDS09366.PubMed

122.

Hashizume R, Smirnov I, Liu S, Phillips JJ, Hyer J, McKnight TR, et al. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. J Neuro-Oncol. 2012;110(3):305–13. doi:10.1007/s11060-012-0973-6.

123.

Veringa SJ, Biesmans D, van Vuurden DG, Jansen MH, Wedekind LE, Horsman I, et al. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PloS One. 2013;8(4):e61512. doi:10.1371/journal.pone.0061512.PubMedCentralPubMed

Titel: Pediatric Brainstem Gliomas: New Understanding Leads to Potential New Treatments for Two Very Different Tumors
verfasst von: Adam L. Green
Mark W. Kieran
Publikationsdatum: 01.03.2015
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 3/2015
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-014-0436-7

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Pediatric Brainstem Gliomas: New Understanding Leads to Potential New Treatments for Two Very Different Tumors

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Surgical Salvage of Recurrent Nasopharyngeal Carcinoma

Metaplastic Breast Cancer: Clinical Overview and Molecular Aberrations for Potential Targeted Therapy

The Neoadjuvant Treatment of Rectal Cancer: A Review

Long-Term Experience with (Laterally) Extended Endopelvic Resection (LEER) in Relapsed Pelvic Malignancies

The Role of Transoral Robotic Surgery in the Management of Oropharyngeal Squamous Cell Carcinoma: a Current Review

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie